Differences in Treatment and Outcome after Treatment with Curative Intent in the Screening and Control Arms of the ERSPC Rotterdam

European Urology

Volumn 68, Issue 2, 2015, Pages 179-182

  Bokhorst, Leonard P ^a   Kranse, Ries ^b   Venderbos, Lionne D F ^a   Salman, Jolanda W ^a   Van Leenders, Geert J L H ^a   Schröder, Fritz H ^a   Bangma, Chris H ^a   Roobol, Monique J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Netherlands Comprehensive Cancer Organization   (Netherlands)

Author keywords

Cure rates; Prostate specific antigen; Prostatic neoplasms; Radical prostatectomy; Radiotherapy; Screening

Indexed keywords

ARTICLE; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER SCREENING; CANCER SURVIVAL; CLINICAL PRACTICE; CONTROL GROUP; DISEASE FREE SURVIVAL; GLEASON SCORE; HUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL (TOPIC); ADVERSE EFFECTS; BLOOD; CANCER GRADING; CANCER STAGING; CHEMORADIOTHERAPY; COMPARATIVE STUDY; CONTROLLED STUDY; EARLY DIAGNOSIS; HEALTH CARE DISPARITY; MALE; MORTALITY; NETHERLANDS; PATHOLOGY; PREDICTIVE VALUE; PROCEDURES; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK FACTOR; TIME; TREATMENT OUTCOME;

CHEMORADIOTHERAPY; DISEASE-FREE SURVIVAL; EARLY DETECTION OF CANCER; HEALTHCARE DISPARITIES; HUMANS; MALE; NEOPLASM GRADING; NEOPLASM STAGING; NETHERLANDS; PREDICTIVE VALUE OF TESTS; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84937426379     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2014.10.008     Document Type: Article

References (11)

1. M.J. Roobol, R. Kranse, C.H. Bangma, and et al. Screening for prostate cancer: results of the Rotterdam Section of the European Randomized Study of Screening for Prostate Cancer Eur Urol 64 2013 530 539
2. L.P. Bokhorst, C.H. Bangma, G.J. van Leenders, and et al. Prostate-specific antigen-based prostate cancer screening: reduction of prostate cancer mortality after correction for nonattendance and contamination in the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer Eur Urol 65 2014 329 336
3. F.H. Schroder, J. Hugosson, S. Carlsson, and et al. Screening for prostate cancer decreases the risk of developing metastatic disease: findings from the European Randomized Study of Screening for Prostate Cancer (ERSPC) Eur Urol 62 2012 745 752
4. M.J. Roobol, W.J. Kirkels, and F.H. Schröder Features and preliminary results of the Dutch centre of the ERSPC (Rotterdam, the Netherlands) BJU Int 92 Suppl 2 2003 48 54
5. M.J. Roobol, and F.H. Schröder European Randomized Study of Screening for Prostate Cancer (ERSPC): rationale, structure and preliminary results BJU Int 92 Suppl 2 2003 1 122
6. A.V. D'Amico, R. Whittington, S.B. Malkowicz, and et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer JAMA 280 1998 969 974
7. E.M. Wever, E.A. Heijnsdijk, G. Draisma, and et al. Treatment of local-regional prostate cancer detected by PSA screening: benefits and harms according to prognostic factors Br J Cancer 108 2013 1971 1977
8. S.W. Duffy, I.D. Nagtegaal, M. Wallis, and et al. Correcting for lead time and length bias in estimating the effect of screen detection on cancer survival Am J Epidemiol 168 2008 98 104
9. M. Bolla, L. Collette, L. Blank, and et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial Lancet 360 2002 103 106
10. Rapportage prostaatkanker SCK rapport 2014. Integraal kankercentrum Nederland Web site. www.iknl.nl.
11. G. Draisma, R. Boer, S.J. Otto, and et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer J Natl Cancer Inst 95 2003 868 878